Disease relevance of GHRP 1

• After 4 h, a bolus of sal, GHRH-44 1 microgram/kg body weight, or GHRP 1 microgram/kg body weight was given iv [1].

High impact information on GHRP 1

• Mechanisms of action of a second generation growth hormone-releasing peptide (Ala-His-D-beta Nal-Ala-Trp-D-Phe-Lys-NH2) in rat anterior pituitary cells [2].
• Similar to GHRH, GHRP-1-induced increases in [Ca2+]i and GH release were inhibited by somatostatin [2].
• The results indicate that whereas GHRP-1 (6-600 micrograms/l) or GHRH (6-600 micrograms/l) alone had no effect on basal triiodothyronine (T3) secretion or cAMP formation, the heptapeptide (6-600 micrograms/l), but not GHRH (6-1200 micrograms/l), dose-dependently inhibited thyrotropin (TSH)-stimulated T3 secretion and cAMP formation [3].
• Synthetic heptapeptide growth hormone-releasing peptide-1 (GHRP-1) potently stimulates GH release in many species, including humans [3].
• It would seem, therefore, that the GHRP-1-induced inhibitory effect on thyroid function is located downstream of cAMP formation, without necessarily excluding an additional inhibitory action at a pre-cAMP site [3].

Associations of GHRP 1 with other chemical compounds

• Particularly note-worthy is that GHRP-6, GHRP-1 AND GHRP-2 all release GH after oral administration [4].

Gene context of GHRP 1

• Growth hormone-releasing activity of growth hormone-releasing peptide-1 (a synthetic heptapeptide) in children and adolescents [5].
• These results additionally demonstrate differences in the mode of action of GHRP-1 and GHRH [3].
• Continuous perifusion of pituitary cells was used to study the effects of a newly synthesized GHRP (GHRP-1 or KP 101) on growth hormone (GH) secretion from ovine pituitary cells and these have been compared to effects of growth hormone-releasing factor (GRF) and the original growth hormone-releasing peptide (GHRP-6) [6].

References